In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Dealmaking Moves The Needle Forward

Executive Summary

Dealmaking is advancing the biosimilar field. Since 2000, the volume of biosimilar deals has grown at a 15% compound annual rate.

Advertisement

Related Content

Deal Watch: Focus Placed On Psoriasis With Recent Purdue, Sienna Deals
Shire Exits Biosimilars, Streamlines Oncology Business
Teva’s 'Key Ingredient' For Growth: Biosimilars
New $350m Site To Build Pfizer’s China Biosimilar Capacity

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel